-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26

Benzinga·05/26/2026 12:52:07
Listen to the news
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $26.